JP2022519829A - 組換え遺伝子発現を調節するための微小環境センサー - Google Patents
組換え遺伝子発現を調節するための微小環境センサー Download PDFInfo
- Publication number
- JP2022519829A JP2022519829A JP2021544538A JP2021544538A JP2022519829A JP 2022519829 A JP2022519829 A JP 2022519829A JP 2021544538 A JP2021544538 A JP 2021544538A JP 2021544538 A JP2021544538 A JP 2021544538A JP 2022519829 A JP2022519829 A JP 2022519829A
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- cells
- cell
- polynucleotide
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000001105 regulatory effect Effects 0.000 title claims abstract description 74
- 230000014509 gene expression Effects 0.000 title description 90
- 108700010039 chimeric receptor Proteins 0.000 claims abstract description 73
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 63
- 238000013518 transcription Methods 0.000 claims abstract description 51
- 230000035897 transcription Effects 0.000 claims abstract description 51
- 238000000034 method Methods 0.000 claims abstract description 44
- 230000001939 inductive effect Effects 0.000 claims abstract description 22
- 238000001727 in vivo Methods 0.000 claims abstract description 14
- 210000004027 cell Anatomy 0.000 claims description 247
- 206010028980 Neoplasm Diseases 0.000 claims description 135
- 108090000623 proteins and genes Proteins 0.000 claims description 85
- 206010021143 Hypoxia Diseases 0.000 claims description 80
- 102000040430 polynucleotide Human genes 0.000 claims description 79
- 108091033319 polynucleotide Proteins 0.000 claims description 79
- 239000002157 polynucleotide Substances 0.000 claims description 79
- 210000002540 macrophage Anatomy 0.000 claims description 77
- 230000001146 hypoxic effect Effects 0.000 claims description 70
- 150000007523 nucleic acids Chemical class 0.000 claims description 53
- 102000039446 nucleic acids Human genes 0.000 claims description 52
- 108020004707 nucleic acids Proteins 0.000 claims description 52
- 239000013598 vector Substances 0.000 claims description 51
- 102000005962 receptors Human genes 0.000 claims description 46
- 108020003175 receptors Proteins 0.000 claims description 46
- -1 CCL4 Proteins 0.000 claims description 35
- 201000011510 cancer Diseases 0.000 claims description 34
- 102000004169 proteins and genes Human genes 0.000 claims description 32
- 210000002865 immune cell Anatomy 0.000 claims description 31
- 210000001616 monocyte Anatomy 0.000 claims description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 26
- 229910052760 oxygen Inorganic materials 0.000 claims description 26
- 108091027981 Response element Proteins 0.000 claims description 25
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 25
- 239000001301 oxygen Substances 0.000 claims description 25
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 24
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 24
- 208000005017 glioblastoma Diseases 0.000 claims description 22
- 208000035475 disorder Diseases 0.000 claims description 21
- 208000027866 inflammatory disease Diseases 0.000 claims description 19
- 108010065805 Interleukin-12 Proteins 0.000 claims description 18
- 102000013462 Interleukin-12 Human genes 0.000 claims description 18
- 210000000066 myeloid cell Anatomy 0.000 claims description 18
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 16
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 16
- 102000019034 Chemokines Human genes 0.000 claims description 15
- 108010012236 Chemokines Proteins 0.000 claims description 15
- 108010074328 Interferon-gamma Proteins 0.000 claims description 14
- 102000004889 Interleukin-6 Human genes 0.000 claims description 14
- 108090001005 Interleukin-6 Proteins 0.000 claims description 14
- 206010060862 Prostate cancer Diseases 0.000 claims description 13
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 13
- 230000004044 response Effects 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 13
- 206010061218 Inflammation Diseases 0.000 claims description 12
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 12
- 230000004054 inflammatory process Effects 0.000 claims description 12
- 210000000822 natural killer cell Anatomy 0.000 claims description 12
- 206010009944 Colon cancer Diseases 0.000 claims description 11
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 claims description 11
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 11
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 11
- 206010033128 Ovarian cancer Diseases 0.000 claims description 11
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 10
- 102000014150 Interferons Human genes 0.000 claims description 10
- 108010050904 Interferons Proteins 0.000 claims description 10
- 102000015696 Interleukins Human genes 0.000 claims description 10
- 108010063738 Interleukins Proteins 0.000 claims description 10
- 108010074108 interleukin-21 Proteins 0.000 claims description 10
- 230000004068 intracellular signaling Effects 0.000 claims description 10
- 206010006187 Breast cancer Diseases 0.000 claims description 9
- 208000026310 Breast neoplasm Diseases 0.000 claims description 9
- 102000004127 Cytokines Human genes 0.000 claims description 9
- 108090000695 Cytokines Proteins 0.000 claims description 9
- 102000006992 Interferon-alpha Human genes 0.000 claims description 9
- 108010047761 Interferon-alpha Proteins 0.000 claims description 9
- 108090000467 Interferon-beta Proteins 0.000 claims description 9
- 102000008070 Interferon-gamma Human genes 0.000 claims description 9
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 claims description 9
- 230000003247 decreasing effect Effects 0.000 claims description 9
- 239000003623 enhancer Substances 0.000 claims description 9
- 239000012634 fragment Substances 0.000 claims description 9
- 229960003130 interferon gamma Drugs 0.000 claims description 9
- 102100023705 C-C motif chemokine 14 Human genes 0.000 claims description 8
- 102100034871 C-C motif chemokine 8 Human genes 0.000 claims description 8
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 claims description 8
- 102100025279 C-X-C motif chemokine 11 Human genes 0.000 claims description 8
- 102100036153 C-X-C motif chemokine 6 Human genes 0.000 claims description 8
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 8
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 8
- 101000978381 Homo sapiens C-C motif chemokine 14 Proteins 0.000 claims description 8
- 101000947178 Homo sapiens Platelet basic protein Proteins 0.000 claims description 8
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 8
- 102100036154 Platelet basic protein Human genes 0.000 claims description 8
- 206010038389 Renal cancer Diseases 0.000 claims description 8
- 208000029742 colonic neoplasm Diseases 0.000 claims description 8
- 230000003834 intracellular effect Effects 0.000 claims description 8
- 201000010982 kidney cancer Diseases 0.000 claims description 8
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 8
- 230000001629 suppression Effects 0.000 claims description 8
- 102100023702 C-C motif chemokine 13 Human genes 0.000 claims description 7
- 102100023688 Eotaxin Human genes 0.000 claims description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 7
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 7
- 230000001684 chronic effect Effects 0.000 claims description 7
- 230000002757 inflammatory effect Effects 0.000 claims description 7
- 229940079322 interferon Drugs 0.000 claims description 7
- 201000007270 liver cancer Diseases 0.000 claims description 7
- 208000014018 liver neoplasm Diseases 0.000 claims description 7
- 201000005202 lung cancer Diseases 0.000 claims description 7
- 208000020816 lung neoplasm Diseases 0.000 claims description 7
- 210000004698 lymphocyte Anatomy 0.000 claims description 7
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 7
- 201000002528 pancreatic cancer Diseases 0.000 claims description 7
- 208000023275 Autoimmune disease Diseases 0.000 claims description 6
- 208000035143 Bacterial infection Diseases 0.000 claims description 6
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims description 6
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims description 6
- 102100028761 Heat shock 70 kDa protein 6 Human genes 0.000 claims description 6
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims description 6
- 101001078680 Homo sapiens Heat shock 70 kDa protein 6 Proteins 0.000 claims description 6
- 102000003996 Interferon-beta Human genes 0.000 claims description 6
- 102000003814 Interleukin-10 Human genes 0.000 claims description 6
- 108090000174 Interleukin-10 Proteins 0.000 claims description 6
- 108010009583 Transforming Growth Factors Proteins 0.000 claims description 6
- 102000009618 Transforming Growth Factors Human genes 0.000 claims description 6
- 102100038183 Tyrosine-protein kinase SYK Human genes 0.000 claims description 6
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 6
- 230000001965 increasing effect Effects 0.000 claims description 6
- 229960001388 interferon-beta Drugs 0.000 claims description 6
- 210000000440 neutrophil Anatomy 0.000 claims description 6
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 5
- 101150037123 APOE gene Proteins 0.000 claims description 5
- 102100021935 C-C motif chemokine 26 Human genes 0.000 claims description 5
- 102100029721 DnaJ homolog subfamily B member 1 Human genes 0.000 claims description 5
- 102100028006 Heme oxygenase 1 Human genes 0.000 claims description 5
- 101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 claims description 5
- 101000866018 Homo sapiens DnaJ homolog subfamily B member 1 Proteins 0.000 claims description 5
- 101001079623 Homo sapiens Heme oxygenase 1 Proteins 0.000 claims description 5
- 101000743488 Homo sapiens V-set and immunoglobulin domain-containing protein 4 Proteins 0.000 claims description 5
- 102100037850 Interferon gamma Human genes 0.000 claims description 5
- 102000000589 Interleukin-1 Human genes 0.000 claims description 5
- 108010002352 Interleukin-1 Proteins 0.000 claims description 5
- 108010002350 Interleukin-2 Proteins 0.000 claims description 5
- 102000000588 Interleukin-2 Human genes 0.000 claims description 5
- 206010029260 Neuroblastoma Diseases 0.000 claims description 5
- 102100021269 Regulator of G-protein signaling 1 Human genes 0.000 claims description 5
- 101710140408 Regulator of G-protein signaling 1 Proteins 0.000 claims description 5
- 206010039491 Sarcoma Diseases 0.000 claims description 5
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 5
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 5
- 102100038296 V-set and immunoglobulin domain-containing protein 4 Human genes 0.000 claims description 5
- 230000004087 circulation Effects 0.000 claims description 5
- 201000000849 skin cancer Diseases 0.000 claims description 5
- 206010046766 uterine cancer Diseases 0.000 claims description 5
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 4
- 102100029470 Apolipoprotein E Human genes 0.000 claims description 4
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 claims description 4
- 102100036842 C-C motif chemokine 19 Human genes 0.000 claims description 4
- 102100036850 C-C motif chemokine 23 Human genes 0.000 claims description 4
- 102100036849 C-C motif chemokine 24 Human genes 0.000 claims description 4
- 102100021936 C-C motif chemokine 27 Human genes 0.000 claims description 4
- 102100032367 C-C motif chemokine 5 Human genes 0.000 claims description 4
- 102100032366 C-C motif chemokine 7 Human genes 0.000 claims description 4
- 101710155833 C-C motif chemokine 8 Proteins 0.000 claims description 4
- 101710098275 C-X-C motif chemokine 10 Proteins 0.000 claims description 4
- 102100025277 C-X-C motif chemokine 13 Human genes 0.000 claims description 4
- 101710085504 C-X-C motif chemokine 6 Proteins 0.000 claims description 4
- 102100032976 CCR4-NOT transcription complex subunit 6 Human genes 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 208000015943 Coeliac disease Diseases 0.000 claims description 4
- 102100037077 Complement C1q subcomponent subunit A Human genes 0.000 claims description 4
- 102100027642 DNA-binding protein inhibitor ID-2 Human genes 0.000 claims description 4
- 101150021185 FGF gene Proteins 0.000 claims description 4
- 101710115997 Gamma-tubulin complex component 2 Proteins 0.000 claims description 4
- 102100033295 Glial cell line-derived neurotrophic factor Human genes 0.000 claims description 4
- 102000009465 Growth Factor Receptors Human genes 0.000 claims description 4
- 108010009202 Growth Factor Receptors Proteins 0.000 claims description 4
- 108010050568 HLA-DM antigens Proteins 0.000 claims description 4
- 101000978379 Homo sapiens C-C motif chemokine 13 Proteins 0.000 claims description 4
- 101000713106 Homo sapiens C-C motif chemokine 19 Proteins 0.000 claims description 4
- 101000713081 Homo sapiens C-C motif chemokine 23 Proteins 0.000 claims description 4
- 101000713078 Homo sapiens C-C motif chemokine 24 Proteins 0.000 claims description 4
- 101000897494 Homo sapiens C-C motif chemokine 27 Proteins 0.000 claims description 4
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 claims description 4
- 101000797758 Homo sapiens C-C motif chemokine 7 Proteins 0.000 claims description 4
- 101000946794 Homo sapiens C-C motif chemokine 8 Proteins 0.000 claims description 4
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 claims description 4
- 101000858060 Homo sapiens C-X-C motif chemokine 11 Proteins 0.000 claims description 4
- 101000858064 Homo sapiens C-X-C motif chemokine 13 Proteins 0.000 claims description 4
- 101000947177 Homo sapiens C-X-C motif chemokine 6 Proteins 0.000 claims description 4
- 101100222381 Homo sapiens CXCL11 gene Proteins 0.000 claims description 4
- 101000740726 Homo sapiens Complement C1q subcomponent subunit A Proteins 0.000 claims description 4
- 101001081582 Homo sapiens DNA-binding protein inhibitor ID-2 Proteins 0.000 claims description 4
- 101000978392 Homo sapiens Eotaxin Proteins 0.000 claims description 4
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 claims description 4
- 101000804764 Homo sapiens Lymphotactin Proteins 0.000 claims description 4
- 101000973997 Homo sapiens Nucleosome assembly protein 1-like 4 Proteins 0.000 claims description 4
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 claims description 4
- 101100369992 Homo sapiens TNFSF10 gene Proteins 0.000 claims description 4
- 101000795117 Homo sapiens Triggering receptor expressed on myeloid cells 2 Proteins 0.000 claims description 4
- 101000838456 Homo sapiens Tubulin alpha-1B chain Proteins 0.000 claims description 4
- 206010020751 Hypersensitivity Diseases 0.000 claims description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 4
- 102000003812 Interleukin-15 Human genes 0.000 claims description 4
- 108090000172 Interleukin-15 Proteins 0.000 claims description 4
- 102000003810 Interleukin-18 Human genes 0.000 claims description 4
- 108090000171 Interleukin-18 Proteins 0.000 claims description 4
- 102100030703 Interleukin-22 Human genes 0.000 claims description 4
- 108010002586 Interleukin-7 Proteins 0.000 claims description 4
- 102100021592 Interleukin-7 Human genes 0.000 claims description 4
- 102100026236 Interleukin-8 Human genes 0.000 claims description 4
- 208000005615 Interstitial Cystitis Diseases 0.000 claims description 4
- 102100035304 Lymphotactin Human genes 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 4
- 101100222387 Mus musculus Cxcl15 gene Proteins 0.000 claims description 4
- 102100040557 Osteopontin Human genes 0.000 claims description 4
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 claims description 4
- 102100033237 Pro-epidermal growth factor Human genes 0.000 claims description 4
- 101710098940 Pro-epidermal growth factor Proteins 0.000 claims description 4
- 101710168942 Sphingosine-1-phosphate phosphatase 1 Proteins 0.000 claims description 4
- 208000000277 Splenic Neoplasms Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 claims description 4
- 108700012411 TNFSF10 Proteins 0.000 claims description 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 4
- 206010052779 Transplant rejections Diseases 0.000 claims description 4
- 102100029678 Triggering receptor expressed on myeloid cells 2 Human genes 0.000 claims description 4
- 102100028969 Tubulin alpha-1B chain Human genes 0.000 claims description 4
- 102100024598 Tumor necrosis factor ligand superfamily member 10 Human genes 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 206010047115 Vasculitis Diseases 0.000 claims description 4
- 206010000496 acne Diseases 0.000 claims description 4
- 208000026935 allergic disease Diseases 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 210000003651 basophil Anatomy 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 claims description 4
- 206010009887 colitis Diseases 0.000 claims description 4
- 208000007784 diverticulitis Diseases 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
- 230000009610 hypersensitivity Effects 0.000 claims description 4
- 208000029081 mast cell activation syndrome Diseases 0.000 claims description 4
- AEUKDPKXTPNBNY-XEYRWQBLSA-N mcp 2 Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)C1=CC=CC=C1 AEUKDPKXTPNBNY-XEYRWQBLSA-N 0.000 claims description 4
- 201000003068 rheumatic fever Diseases 0.000 claims description 4
- 206010039083 rhinitis Diseases 0.000 claims description 4
- 201000000306 sarcoidosis Diseases 0.000 claims description 4
- 201000002471 spleen cancer Diseases 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 4
- 239000013603 viral vector Substances 0.000 claims description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 3
- 102100024341 10 kDa heat shock protein, mitochondrial Human genes 0.000 claims description 3
- SIVJKYRAPQKLIM-UHFFFAOYSA-N 3-(3,4-difluorophenyl)-n-(3-fluoro-5-morpholin-4-ylphenyl)propanamide Chemical compound C=1C(N2CCOCC2)=CC(F)=CC=1NC(=O)CCC1=CC=C(F)C(F)=C1 SIVJKYRAPQKLIM-UHFFFAOYSA-N 0.000 claims description 3
- 102100036183 5'-3' exonuclease PLD4 Human genes 0.000 claims description 3
- 102100038222 60 kDa heat shock protein, mitochondrial Human genes 0.000 claims description 3
- 102100036006 Adenosine receptor A3 Human genes 0.000 claims description 3
- 102100023809 Adipocyte plasma membrane-associated protein Human genes 0.000 claims description 3
- 102100027265 Aldo-keto reductase family 1 member B1 Human genes 0.000 claims description 3
- 102100033312 Alpha-2-macroglobulin Human genes 0.000 claims description 3
- 102100040412 Amyloid beta A4 precursor protein-binding family B member 1-interacting protein Human genes 0.000 claims description 3
- 101000957318 Arabidopsis thaliana Lysophospholipid acyltransferase 2 Proteins 0.000 claims description 3
- 102100022278 Arachidonate 5-lipoxygenase-activating protein Human genes 0.000 claims description 3
- 102100024358 Arf-GAP with dual PH domain-containing protein 2 Human genes 0.000 claims description 3
- 208000011594 Autoinflammatory disease Diseases 0.000 claims description 3
- 102100023045 Band 4.1-like protein 2 Human genes 0.000 claims description 3
- 102100022794 Bestrophin-1 Human genes 0.000 claims description 3
- 102100029945 Beta-galactoside alpha-2,6-sialyltransferase 1 Human genes 0.000 claims description 3
- 101710112613 C-C motif chemokine 13 Proteins 0.000 claims description 3
- 102100034673 C-C motif chemokine 3-like 1 Human genes 0.000 claims description 3
- 102100021984 C-C motif chemokine 4-like Human genes 0.000 claims description 3
- 102100036166 C-X-C chemokine receptor type 1 Human genes 0.000 claims description 3
- 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 claims description 3
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 claims description 3
- 102100031658 C-X-C chemokine receptor type 5 Human genes 0.000 claims description 3
- 102100025618 C-X-C chemokine receptor type 6 Human genes 0.000 claims description 3
- 102100021703 C3a anaphylatoxin chemotactic receptor Human genes 0.000 claims description 3
- 102100035793 CD83 antigen Human genes 0.000 claims description 3
- 108090000835 CX3C Chemokine Receptor 1 Proteins 0.000 claims description 3
- 102100039196 CX3C chemokine receptor 1 Human genes 0.000 claims description 3
- 102100023074 Calcium-activated potassium channel subunit beta-1 Human genes 0.000 claims description 3
- 102000009410 Chemokine receptor Human genes 0.000 claims description 3
- 108050000299 Chemokine receptor Proteins 0.000 claims description 3
- 102100026190 Class E basic helix-loop-helix protein 41 Human genes 0.000 claims description 3
- 102100022133 Complement C3 Human genes 0.000 claims description 3
- 108010016788 Cyclin-Dependent Kinase Inhibitor p21 Proteins 0.000 claims description 3
- 102100033270 Cyclin-dependent kinase inhibitor 1 Human genes 0.000 claims description 3
- 102100026139 DNA damage-inducible transcript 4 protein Human genes 0.000 claims description 3
- 102100020977 DnaJ homolog subfamily A member 1 Human genes 0.000 claims description 3
- 102100023227 E3 SUMO-protein ligase EGR2 Human genes 0.000 claims description 3
- 108060006698 EGF receptor Proteins 0.000 claims description 3
- 102000001301 EGF receptor Human genes 0.000 claims description 3
- 102100025137 Early activation antigen CD69 Human genes 0.000 claims description 3
- 102100027259 Ena/VASP-like protein Human genes 0.000 claims description 3
- 101710139422 Eotaxin Proteins 0.000 claims description 3
- 102100029327 FERM domain-containing protein 4A Human genes 0.000 claims description 3
- 102100036089 Fascin Human genes 0.000 claims description 3
- 102100021245 G-protein coupled receptor 183 Human genes 0.000 claims description 3
- 102100028953 Gelsolin Human genes 0.000 claims description 3
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 3
- 102000058080 Glucose Transporter Type 5 Human genes 0.000 claims description 3
- 108010092372 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Proteins 0.000 claims description 3
- 102000016355 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Human genes 0.000 claims description 3
- 102100028113 Granulocyte-macrophage colony-stimulating factor receptor subunit alpha Human genes 0.000 claims description 3
- 102100033079 HLA class II histocompatibility antigen, DM alpha chain Human genes 0.000 claims description 3
- 102100031618 HLA class II histocompatibility antigen, DP beta 1 chain Human genes 0.000 claims description 3
- 102100036241 HLA class II histocompatibility antigen, DQ beta 1 chain Human genes 0.000 claims description 3
- 108010045483 HLA-DPB1 antigen Proteins 0.000 claims description 3
- 108010065026 HLA-DQB1 antigen Proteins 0.000 claims description 3
- 101150096895 HSPB1 gene Proteins 0.000 claims description 3
- 102100040352 Heat shock 70 kDa protein 1A Human genes 0.000 claims description 3
- 102100040407 Heat shock 70 kDa protein 1B Human genes 0.000 claims description 3
- 102100032510 Heat shock protein HSP 90-beta Human genes 0.000 claims description 3
- 102100039165 Heat shock protein beta-1 Human genes 0.000 claims description 3
- 108010007707 Hepatitis A Virus Cellular Receptor 2 Proteins 0.000 claims description 3
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 3
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 claims description 3
- 101000980303 Homo sapiens 10 kDa heat shock protein, mitochondrial Proteins 0.000 claims description 3
- 101001074382 Homo sapiens 5'-3' exonuclease PLD4 Proteins 0.000 claims description 3
- 101000883686 Homo sapiens 60 kDa heat shock protein, mitochondrial Proteins 0.000 claims description 3
- 101000783645 Homo sapiens Adenosine receptor A3 Proteins 0.000 claims description 3
- 101000684373 Homo sapiens Adipocyte plasma membrane-associated protein Proteins 0.000 claims description 3
- 101000836540 Homo sapiens Aldo-keto reductase family 1 member B1 Proteins 0.000 claims description 3
- 101000799972 Homo sapiens Alpha-2-macroglobulin Proteins 0.000 claims description 3
- 101000964223 Homo sapiens Amyloid beta A4 precursor protein-binding family B member 1-interacting protein Proteins 0.000 claims description 3
- 101000755875 Homo sapiens Arachidonate 5-lipoxygenase-activating protein Proteins 0.000 claims description 3
- 101000832784 Homo sapiens Arf-GAP with dual PH domain-containing protein 2 Proteins 0.000 claims description 3
- 101100218714 Homo sapiens BHLHE41 gene Proteins 0.000 claims description 3
- 101001049977 Homo sapiens Band 4.1-like protein 2 Proteins 0.000 claims description 3
- 101000903449 Homo sapiens Bestrophin-1 Proteins 0.000 claims description 3
- 101000863864 Homo sapiens Beta-galactoside alpha-2,6-sialyltransferase 1 Proteins 0.000 claims description 3
- 101000946370 Homo sapiens C-C motif chemokine 3-like 1 Proteins 0.000 claims description 3
- 101000896959 Homo sapiens C-C motif chemokine 4-like Proteins 0.000 claims description 3
- 101000947174 Homo sapiens C-X-C chemokine receptor type 1 Proteins 0.000 claims description 3
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 claims description 3
- 101000922405 Homo sapiens C-X-C chemokine receptor type 5 Proteins 0.000 claims description 3
- 101000856683 Homo sapiens C-X-C chemokine receptor type 6 Proteins 0.000 claims description 3
- 101000896583 Homo sapiens C3a anaphylatoxin chemotactic receptor Proteins 0.000 claims description 3
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims description 3
- 101001049849 Homo sapiens Calcium-activated potassium channel subunit beta-1 Proteins 0.000 claims description 3
- 101000901154 Homo sapiens Complement C3 Proteins 0.000 claims description 3
- 101000912753 Homo sapiens DNA damage-inducible transcript 4 protein Proteins 0.000 claims description 3
- 101000931227 Homo sapiens DnaJ homolog subfamily A member 1 Proteins 0.000 claims description 3
- 101001049692 Homo sapiens E3 SUMO-protein ligase EGR2 Proteins 0.000 claims description 3
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 claims description 3
- 101001057143 Homo sapiens Ena/VASP-like protein Proteins 0.000 claims description 3
- 101000866286 Homo sapiens Excitatory amino acid transporter 1 Proteins 0.000 claims description 3
- 101001062454 Homo sapiens FERM domain-containing protein 4A Proteins 0.000 claims description 3
- 101001021925 Homo sapiens Fascin Proteins 0.000 claims description 3
- 101001040801 Homo sapiens G-protein coupled receptor 183 Proteins 0.000 claims description 3
- 101001059150 Homo sapiens Gelsolin Proteins 0.000 claims description 3
- 101000916625 Homo sapiens Granulocyte-macrophage colony-stimulating factor receptor subunit alpha Proteins 0.000 claims description 3
- 101001037759 Homo sapiens Heat shock 70 kDa protein 1A Proteins 0.000 claims description 3
- 101001037968 Homo sapiens Heat shock 70 kDa protein 1B Proteins 0.000 claims description 3
- 101001016856 Homo sapiens Heat shock protein HSP 90-beta Proteins 0.000 claims description 3
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 claims description 3
- 101001035137 Homo sapiens Homocysteine-responsive endoplasmic reticulum-resident ubiquitin-like domain member 1 protein Proteins 0.000 claims description 3
- 101001003310 Homo sapiens Immediate early response gene 5 protein Proteins 0.000 claims description 3
- 101000809239 Homo sapiens Inactive ubiquitin carboxyl-terminal hydrolase 53 Proteins 0.000 claims description 3
- 101001001420 Homo sapiens Interferon gamma receptor 1 Proteins 0.000 claims description 3
- 101000959664 Homo sapiens Interferon-induced protein 44-like Proteins 0.000 claims description 3
- 101001063370 Homo sapiens Legumain Proteins 0.000 claims description 3
- 101000984186 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 4 Proteins 0.000 claims description 3
- 101000978210 Homo sapiens Leukotriene C4 synthase Proteins 0.000 claims description 3
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 3
- 101001038034 Homo sapiens Lysophosphatidic acid receptor 6 Proteins 0.000 claims description 3
- 101001113698 Homo sapiens Lysophosphatidylcholine acyltransferase 2 Proteins 0.000 claims description 3
- 101001014059 Homo sapiens Metallothionein-2 Proteins 0.000 claims description 3
- 101000970561 Homo sapiens Myc box-dependent-interacting protein 1 Proteins 0.000 claims description 3
- 101001109700 Homo sapiens Nuclear receptor subfamily 4 group A member 1 Proteins 0.000 claims description 3
- 101001086535 Homo sapiens Olfactomedin-like protein 3 Proteins 0.000 claims description 3
- 101000772905 Homo sapiens Polyubiquitin-B Proteins 0.000 claims description 3
- 101001009552 Homo sapiens Probable G-protein coupled receptor 34 Proteins 0.000 claims description 3
- 101000983583 Homo sapiens Procathepsin L Proteins 0.000 claims description 3
- 101000933604 Homo sapiens Protein BTG2 Proteins 0.000 claims description 3
- 101000880044 Homo sapiens SLIT-ROBO Rho GTPase-activating protein 3 Proteins 0.000 claims description 3
- 101001041393 Homo sapiens Serine protease HTRA1 Proteins 0.000 claims description 3
- 101000691614 Homo sapiens Serine/threonine-protein kinase PLK3 Proteins 0.000 claims description 3
- 101000864800 Homo sapiens Serine/threonine-protein kinase Sgk1 Proteins 0.000 claims description 3
- 101000764653 Homo sapiens Transmembrane domain-containing protein TMIGD3 Proteins 0.000 claims description 3
- 101000802094 Homo sapiens mRNA decay activator protein ZFP36L1 Proteins 0.000 claims description 3
- 102100039923 Homocysteine-responsive endoplasmic reticulum-resident ubiquitin-like domain member 1 protein Human genes 0.000 claims description 3
- 102100020688 Immediate early response gene 5 protein Human genes 0.000 claims description 3
- 102100038425 Inactive ubiquitin carboxyl-terminal hydrolase 53 Human genes 0.000 claims description 3
- 102100026720 Interferon beta Human genes 0.000 claims description 3
- 102100035678 Interferon gamma receptor 1 Human genes 0.000 claims description 3
- 102100039953 Interferon-induced protein 44-like Human genes 0.000 claims description 3
- 102000003816 Interleukin-13 Human genes 0.000 claims description 3
- 108090000176 Interleukin-13 Proteins 0.000 claims description 3
- 108090000978 Interleukin-4 Proteins 0.000 claims description 3
- 102000004388 Interleukin-4 Human genes 0.000 claims description 3
- 108010038501 Interleukin-6 Receptors Proteins 0.000 claims description 3
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 claims description 3
- 108010018951 Interleukin-8B Receptors Proteins 0.000 claims description 3
- 102100030985 Legumain Human genes 0.000 claims description 3
- 102100025578 Leukocyte immunoglobulin-like receptor subfamily B member 4 Human genes 0.000 claims description 3
- 102100023758 Leukotriene C4 synthase Human genes 0.000 claims description 3
- 108010031801 Lipopolysaccharide Receptors Proteins 0.000 claims description 3
- 102000005482 Lipopolysaccharide Receptors Human genes 0.000 claims description 3
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 claims description 3
- 102100040406 Lysophosphatidic acid receptor 6 Human genes 0.000 claims description 3
- 102100023738 Lysophosphatidylcholine acyltransferase 2 Human genes 0.000 claims description 3
- 102100031347 Metallothionein-2 Human genes 0.000 claims description 3
- 102100025751 Mothers against decapentaplegic homolog 2 Human genes 0.000 claims description 3
- 101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 claims description 3
- 102100025748 Mothers against decapentaplegic homolog 3 Human genes 0.000 claims description 3
- 101710143111 Mothers against decapentaplegic homolog 3 Proteins 0.000 claims description 3
- 102100021970 Myc box-dependent-interacting protein 1 Human genes 0.000 claims description 3
- 108010063737 Myristoylated Alanine-Rich C Kinase Substrate Proteins 0.000 claims description 3
- 102000015695 Myristoylated Alanine-Rich C Kinase Substrate Human genes 0.000 claims description 3
- 102100022679 Nuclear receptor subfamily 4 group A member 1 Human genes 0.000 claims description 3
- 102100032750 Olfactomedin-like protein 3 Human genes 0.000 claims description 3
- 208000005141 Otitis Diseases 0.000 claims description 3
- 102100025386 Oxidized low-density lipoprotein receptor 1 Human genes 0.000 claims description 3
- 108091008606 PDGF receptors Proteins 0.000 claims description 3
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 claims description 3
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 claims description 3
- 102100030432 Polyubiquitin-B Human genes 0.000 claims description 3
- 102100030263 Probable G-protein coupled receptor 34 Human genes 0.000 claims description 3
- 102100026534 Procathepsin L Human genes 0.000 claims description 3
- 102100026034 Protein BTG2 Human genes 0.000 claims description 3
- 102100035773 Regulator of G-protein signaling 10 Human genes 0.000 claims description 3
- 101710148338 Regulator of G-protein signaling 10 Proteins 0.000 claims description 3
- 102000012977 SLC1A3 Human genes 0.000 claims description 3
- 108091006301 SLC2A5 Proteins 0.000 claims description 3
- 102100037372 SLIT-ROBO Rho GTPase-activating protein 2 Human genes 0.000 claims description 3
- 102000001332 SRC Human genes 0.000 claims description 3
- 102100021119 Serine protease HTRA1 Human genes 0.000 claims description 3
- 102100026209 Serine/threonine-protein kinase PLK3 Human genes 0.000 claims description 3
- 102100030070 Serine/threonine-protein kinase Sgk1 Human genes 0.000 claims description 3
- 102100026228 Transmembrane domain-containing protein TMIGD3 Human genes 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 3
- 102000003675 cytokine receptors Human genes 0.000 claims description 3
- 108010057085 cytokine receptors Proteins 0.000 claims description 3
- 210000003979 eosinophil Anatomy 0.000 claims description 3
- 230000008472 epithelial growth Effects 0.000 claims description 3
- 102000006815 folate receptor Human genes 0.000 claims description 3
- 108020005243 folate receptor Proteins 0.000 claims description 3
- 210000005260 human cell Anatomy 0.000 claims description 3
- 102100034702 mRNA decay activator protein ZFP36L1 Human genes 0.000 claims description 3
- 210000004962 mammalian cell Anatomy 0.000 claims description 3
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 claims description 3
- 210000000581 natural killer T-cell Anatomy 0.000 claims description 3
- 230000010410 reperfusion Effects 0.000 claims description 3
- 108091005418 scavenger receptor class E Proteins 0.000 claims description 3
- 230000000638 stimulation Effects 0.000 claims description 3
- 102100024682 14-3-3 protein eta Human genes 0.000 claims description 2
- 108010082808 4-1BB Ligand Proteins 0.000 claims description 2
- 102100022861 ADP-ribosylation factor-like protein 5A Human genes 0.000 claims description 2
- 102100031934 Adhesion G-protein coupled receptor G1 Human genes 0.000 claims description 2
- 102100027954 BAG family molecular chaperone regulator 3 Human genes 0.000 claims description 2
- 102100032937 CD40 ligand Human genes 0.000 claims description 2
- 102100025221 CD70 antigen Human genes 0.000 claims description 2
- 102100033722 Cholesterol 25-hydroxylase Human genes 0.000 claims description 2
- 102100022820 Disintegrin and metalloproteinase domain-containing protein 28 Human genes 0.000 claims description 2
- 102100031153 Growth arrest and DNA damage-inducible protein GADD45 beta Human genes 0.000 claims description 2
- 102100029966 HLA class II histocompatibility antigen, DP alpha 1 chain Human genes 0.000 claims description 2
- 102100036242 HLA class II histocompatibility antigen, DQ alpha 2 chain Human genes 0.000 claims description 2
- 108010093061 HLA-DPA1 antigen Proteins 0.000 claims description 2
- 108010086786 HLA-DQA1 antigen Proteins 0.000 claims description 2
- 102100031624 Heat shock protein 105 kDa Human genes 0.000 claims description 2
- 101000760084 Homo sapiens 14-3-3 protein eta Proteins 0.000 claims description 2
- 101000974441 Homo sapiens ADP-ribosylation factor-like protein 5A Proteins 0.000 claims description 2
- 101000775042 Homo sapiens Adhesion G-protein coupled receptor G1 Proteins 0.000 claims description 2
- 101000697871 Homo sapiens BAG family molecular chaperone regulator 3 Proteins 0.000 claims description 2
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims description 2
- 101000944583 Homo sapiens Cholesterol 25-hydroxylase Proteins 0.000 claims description 2
- 101000756756 Homo sapiens Disintegrin and metalloproteinase domain-containing protein 28 Proteins 0.000 claims description 2
- 101001066164 Homo sapiens Growth arrest and DNA damage-inducible protein GADD45 beta Proteins 0.000 claims description 2
- 101000866478 Homo sapiens Heat shock protein 105 kDa Proteins 0.000 claims description 2
- 101001109689 Homo sapiens Nuclear receptor subfamily 4 group A member 3 Proteins 0.000 claims description 2
- 101000598051 Homo sapiens Transmembrane protein 119 Proteins 0.000 claims description 2
- 102000004083 Lymphotoxin-alpha Human genes 0.000 claims description 2
- 108090000542 Lymphotoxin-alpha Proteins 0.000 claims description 2
- 102100022673 Nuclear receptor subfamily 4 group A member 3 Human genes 0.000 claims description 2
- 102100027611 Rho-related GTP-binding protein RhoB Human genes 0.000 claims description 2
- 101150054980 Rhob gene Proteins 0.000 claims description 2
- 102000002689 Toll-like receptor Human genes 0.000 claims description 2
- 108020000411 Toll-like receptor Proteins 0.000 claims description 2
- 102100037029 Transmembrane protein 119 Human genes 0.000 claims description 2
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 claims description 2
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 claims description 2
- 102100032100 Tumor necrosis factor ligand superfamily member 8 Human genes 0.000 claims description 2
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 claims description 2
- 230000012010 growth Effects 0.000 claims description 2
- 230000031146 intracellular signal transduction Effects 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 229940127557 pharmaceutical product Drugs 0.000 claims description 2
- 230000002792 vascular Effects 0.000 claims description 2
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 claims 4
- 210000000106 sweat gland Anatomy 0.000 claims 2
- 102000012335 Plasminogen Activator Inhibitor 1 Human genes 0.000 claims 1
- 230000003511 endothelial effect Effects 0.000 claims 1
- 108700019146 Transgenes Proteins 0.000 abstract description 51
- 239000000203 mixture Substances 0.000 abstract description 17
- 108060001084 Luciferase Proteins 0.000 description 56
- 239000005089 Luciferase Substances 0.000 description 49
- 108700008625 Reporter Genes Proteins 0.000 description 16
- 210000001744 T-lymphocyte Anatomy 0.000 description 16
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 12
- 230000007423 decrease Effects 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 230000006870 function Effects 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 11
- 230000004083 survival effect Effects 0.000 description 11
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 10
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 10
- 230000011664 signaling Effects 0.000 description 10
- 108091000080 Phosphotransferase Proteins 0.000 description 8
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 8
- 238000004020 luminiscence type Methods 0.000 description 8
- 102000020233 phosphotransferase Human genes 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 7
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 7
- 101710149136 Protein Vpr Proteins 0.000 description 7
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 230000007954 hypoxia Effects 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 210000001185 bone marrow Anatomy 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 210000005259 peripheral blood Anatomy 0.000 description 6
- 239000011886 peripheral blood Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 102100023990 60S ribosomal protein L17 Human genes 0.000 description 5
- 102000014914 Carrier Proteins Human genes 0.000 description 5
- 208000032612 Glial tumor Diseases 0.000 description 5
- 206010018338 Glioma Diseases 0.000 description 5
- 101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 description 5
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 5
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 108091008324 binding proteins Proteins 0.000 description 5
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 5
- 231100000433 cytotoxic Toxicity 0.000 description 5
- 230000001472 cytotoxic effect Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000001506 immunosuppresive effect Effects 0.000 description 5
- 238000009169 immunotherapy Methods 0.000 description 5
- 229940047122 interleukins Drugs 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 201000001441 melanoma Diseases 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 230000000770 proinflammatory effect Effects 0.000 description 5
- 229920002477 rna polymer Polymers 0.000 description 5
- VDABVNMGKGUPEY-UHFFFAOYSA-N 6-carboxyfluorescein succinimidyl ester Chemical compound C=1C(O)=CC=C2C=1OC1=CC(O)=CC=C1C2(C1=C2)OC(=O)C1=CC=C2C(=O)ON1C(=O)CCC1=O VDABVNMGKGUPEY-UHFFFAOYSA-N 0.000 description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 4
- 241000713666 Lentivirus Species 0.000 description 4
- 238000012300 Sequence Analysis Methods 0.000 description 4
- 108091008874 T cell receptors Proteins 0.000 description 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 4
- 108010052104 Viral Regulatory and Accessory Proteins Proteins 0.000 description 4
- 238000002659 cell therapy Methods 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 210000002536 stromal cell Anatomy 0.000 description 4
- 230000001839 systemic circulation Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 238000010361 transduction Methods 0.000 description 4
- 230000026683 transduction Effects 0.000 description 4
- 210000004981 tumor-associated macrophage Anatomy 0.000 description 4
- 101100339431 Arabidopsis thaliana HMGB2 gene Proteins 0.000 description 3
- 206010005949 Bone cancer Diseases 0.000 description 3
- 208000018084 Bone neoplasm Diseases 0.000 description 3
- 102100034289 Deoxynucleoside triphosphate triphosphohydrolase SAMHD1 Human genes 0.000 description 3
- 102100023226 Early growth response protein 1 Human genes 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 108700010013 HMGB1 Proteins 0.000 description 3
- 101150021904 HMGB1 gene Proteins 0.000 description 3
- 102100037907 High mobility group protein B1 Human genes 0.000 description 3
- 101001049697 Homo sapiens Early growth response protein 1 Proteins 0.000 description 3
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 3
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 3
- 102000043129 MHC class I family Human genes 0.000 description 3
- 108091054437 MHC class I family Proteins 0.000 description 3
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 3
- 101710127797 Macrophage colony-stimulating factor 1 Proteins 0.000 description 3
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 description 3
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 description 3
- 108091005461 Nucleic proteins Proteins 0.000 description 3
- 108700019718 SAM Domain and HD Domain-Containing Protein 1 Proteins 0.000 description 3
- 101150114242 SAMHD1 gene Proteins 0.000 description 3
- 230000006052 T cell proliferation Effects 0.000 description 3
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 3
- 101710201961 Virion infectivity factor Proteins 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 239000012830 cancer therapeutic Substances 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 230000003284 homeostatic effect Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 210000005008 immunosuppressive cell Anatomy 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229940047124 interferons Drugs 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 210000000274 microglia Anatomy 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000004980 monocyte derived macrophage Anatomy 0.000 description 3
- 239000003642 reactive oxygen metabolite Substances 0.000 description 3
- 230000001177 retroviral effect Effects 0.000 description 3
- 125000006850 spacer group Chemical group 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 102100039396 C-X-C motif chemokine 16 Human genes 0.000 description 2
- 238000011357 CAR T-cell therapy Methods 0.000 description 2
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 2
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 2
- 102100022882 Deoxyribonuclease-2-alpha Human genes 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 102000012804 EPCAM Human genes 0.000 description 2
- 101150084967 EPCAM gene Proteins 0.000 description 2
- 102100021717 Early growth response protein 3 Human genes 0.000 description 2
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000889133 Homo sapiens C-X-C motif chemokine 16 Proteins 0.000 description 2
- 101000933636 Homo sapiens Complement C1q subcomponent subunit C Proteins 0.000 description 2
- 101000902850 Homo sapiens Deoxyribonuclease-2-alpha Proteins 0.000 description 2
- 101000896450 Homo sapiens Early growth response protein 3 Proteins 0.000 description 2
- 101000728860 Homo sapiens Ribonuclease T2 Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 108010017736 Leukocyte Immunoglobulin-like Receptor B1 Proteins 0.000 description 2
- 102100025584 Leukocyte immunoglobulin-like receptor subfamily B member 1 Human genes 0.000 description 2
- 102100024573 Macrophage-capping protein Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 101100508818 Mus musculus Inpp5k gene Proteins 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 2
- 101100366438 Rattus norvegicus Sphkap gene Proteins 0.000 description 2
- 102100029683 Ribonuclease T2 Human genes 0.000 description 2
- 108091006686 SLCO2B1 Proteins 0.000 description 2
- 102100027264 Solute carrier organic anion transporter family member 2B1 Human genes 0.000 description 2
- 101150057140 TACSTD1 gene Proteins 0.000 description 2
- 102000006601 Thymidine Kinase Human genes 0.000 description 2
- 108020004440 Thymidine kinase Proteins 0.000 description 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 2
- 108010060804 Toll-Like Receptor 4 Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 108010046516 Wheat Germ Agglutinins Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000005415 bioluminescence Methods 0.000 description 2
- 230000029918 bioluminescence Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000000973 chemotherapeutic effect Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 229940040731 human interleukin-12 Drugs 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 102000027596 immune receptors Human genes 0.000 description 2
- 108091008915 immune receptors Proteins 0.000 description 2
- 230000006058 immune tolerance Effects 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000005007 innate immune system Anatomy 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 108020001756 ligand binding domains Proteins 0.000 description 2
- 201000003265 lymphadenitis Diseases 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 238000000513 principal component analysis Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 150000003212 purines Chemical class 0.000 description 2
- 150000003230 pyrimidines Chemical class 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 210000004243 sweat Anatomy 0.000 description 2
- 229960001603 tamoxifen Drugs 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 208000037956 transmissible mink encephalopathy Diseases 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- 235000011178 triphosphate Nutrition 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- FVFVNNKYKYZTJU-UHFFFAOYSA-N 6-chloro-1,3,5-triazine-2,4-diamine Chemical group NC1=NC(N)=NC(Cl)=N1 FVFVNNKYKYZTJU-UHFFFAOYSA-N 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical group N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 102100028220 ABI gene family member 3 Human genes 0.000 description 1
- 102000017919 ADRB2 Human genes 0.000 description 1
- 102100030834 AT-rich interactive domain-containing protein 5A Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 101150065475 C1QA gene Proteins 0.000 description 1
- 101150084780 C1qb gene Proteins 0.000 description 1
- 101150071258 C3 gene Proteins 0.000 description 1
- 102100032957 C5a anaphylatoxin chemotactic receptor 1 Human genes 0.000 description 1
- 101710098483 C5a anaphylatoxin chemotactic receptor 1 Proteins 0.000 description 1
- 238000011523 CAR-T cell immunotherapy Methods 0.000 description 1
- 101150052909 CCL2 gene Proteins 0.000 description 1
- 102100021992 CD209 antigen Human genes 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 101150053778 CSF1R gene Proteins 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102100033471 Cbp/p300-interacting transactivator 2 Human genes 0.000 description 1
- 102000011068 Cdc42 Human genes 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010052358 Colorectal cancer metastatic Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102100037085 Complement C1q subcomponent subunit B Human genes 0.000 description 1
- 102100025849 Complement C1q subcomponent subunit C Human genes 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 102100030497 Cytochrome c Human genes 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 101150007095 Dnajb1 gene Proteins 0.000 description 1
- 101150003173 Dnase2 gene Proteins 0.000 description 1
- 101100312924 Drosophila melanogaster Taf8 gene Proteins 0.000 description 1
- 101150002621 EPO gene Proteins 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 108700041152 Endoplasmic Reticulum Chaperone BiP Proteins 0.000 description 1
- 102100021451 Endoplasmic reticulum chaperone BiP Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102100038595 Estrogen receptor Human genes 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010029961 Filgrastim Proteins 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 102100031258 HLA class II histocompatibility antigen, DM beta chain Human genes 0.000 description 1
- 101150112743 HSPA5 gene Proteins 0.000 description 1
- 101150033930 HSPA6 gene Proteins 0.000 description 1
- 102100027421 Heat shock cognate 71 kDa protein Human genes 0.000 description 1
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 102100026119 High affinity immunoglobulin gamma Fc receptor IB Human genes 0.000 description 1
- 101000724234 Homo sapiens ABI gene family member 3 Proteins 0.000 description 1
- 101000792952 Homo sapiens AT-rich interactive domain-containing protein 5A Proteins 0.000 description 1
- 101000959437 Homo sapiens Beta-2 adrenergic receptor Proteins 0.000 description 1
- 101000897416 Homo sapiens CD209 antigen Proteins 0.000 description 1
- 101000944098 Homo sapiens Cbp/p300-interacting transactivator 2 Proteins 0.000 description 1
- 101000740680 Homo sapiens Complement C1q subcomponent subunit B Proteins 0.000 description 1
- 101000726355 Homo sapiens Cytochrome c Proteins 0.000 description 1
- 101001080568 Homo sapiens Heat shock cognate 71 kDa protein Proteins 0.000 description 1
- 101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 description 1
- 101000913077 Homo sapiens High affinity immunoglobulin gamma Fc receptor IB Proteins 0.000 description 1
- 101000913082 Homo sapiens IgGFc-binding protein Proteins 0.000 description 1
- 101000580021 Homo sapiens Inactive rhomboid protein 2 Proteins 0.000 description 1
- 101001090713 Homo sapiens L-lactate dehydrogenase A chain Proteins 0.000 description 1
- 101000874532 Homo sapiens Lactosylceramide 1,3-N-acetyl-beta-D-glucosaminyltransferase Proteins 0.000 description 1
- 101000991061 Homo sapiens MHC class I polypeptide-related sequence B Proteins 0.000 description 1
- 101000576894 Homo sapiens Macrophage mannose receptor 1 Proteins 0.000 description 1
- 101001018258 Homo sapiens Macrophage receptor MARCO Proteins 0.000 description 1
- 101000760817 Homo sapiens Macrophage-capping protein Proteins 0.000 description 1
- 101001123859 Homo sapiens Sialidase-1 Proteins 0.000 description 1
- 101000652226 Homo sapiens Suppressor of cytokine signaling 6 Proteins 0.000 description 1
- 101100426014 Homo sapiens TREM2 gene Proteins 0.000 description 1
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 1
- 101001065732 Homo sapiens U6 snRNA-associated Sm-like protein LSm6 Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 102100026103 IgGFc-binding protein Human genes 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 102100027537 Inactive rhomboid protein 2 Human genes 0.000 description 1
- 102100034671 L-lactate dehydrogenase A chain Human genes 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000002146 L01XE16 - Crizotinib Substances 0.000 description 1
- 102100035655 Lactosylceramide 1,3-N-acetyl-beta-D-glucosaminyltransferase Human genes 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 102100030300 MHC class I polypeptide-related sequence B Human genes 0.000 description 1
- 101710150918 Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 1
- 102100025354 Macrophage mannose receptor 1 Human genes 0.000 description 1
- 102100033272 Macrophage receptor MARCO Human genes 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- XOGTZOOQQBDUSI-UHFFFAOYSA-M Mesna Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 101710164418 Movement protein TGB2 Proteins 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 102000016979 Other receptors Human genes 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 101150108119 PDS gene Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101710149109 Protein Vpx Proteins 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical group C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 101150109676 Rgs1 gene Proteins 0.000 description 1
- 101150030803 SLC26A4 gene Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 102100021225 Serine hydroxymethyltransferase, cytosolic Human genes 0.000 description 1
- 108700025832 Serum Response Element Proteins 0.000 description 1
- 102100028760 Sialidase-1 Human genes 0.000 description 1
- 241000713311 Simian immunodeficiency virus Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 102100030529 Suppressor of cytokine signaling 7 Human genes 0.000 description 1
- 101150085127 TREM2 gene Proteins 0.000 description 1
- 101150052918 TUBA1B gene Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 102100032068 U6 snRNA-associated Sm-like protein LSm6 Human genes 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 229960001372 aprepitant Drugs 0.000 description 1
- ATALOFNDEOCMKK-OITMNORJSA-N aprepitant Chemical compound O([C@@H]([C@@H]1C=2C=CC(F)=CC=2)O[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCN1CC1=NNC(=O)N1 ATALOFNDEOCMKK-OITMNORJSA-N 0.000 description 1
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 1
- 229960002594 arsenic trioxide Drugs 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- BMQGVNUXMIRLCK-OAGWZNDDSA-N cabazitaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OC)C(=O)C1=CC=CC=C1 BMQGVNUXMIRLCK-OAGWZNDDSA-N 0.000 description 1
- 229960001573 cabazitaxel Drugs 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 108010051348 cdc42 GTP-Binding Protein Proteins 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 201000002797 childhood leukemia Diseases 0.000 description 1
- 208000011654 childhood malignant neoplasm Diseases 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 1
- 229960005061 crizotinib Drugs 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000007435 diagnostic evaluation Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000000222 eosinocyte Anatomy 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 230000008995 epigenetic change Effects 0.000 description 1
- 208000010932 epithelial neoplasm Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 229960004177 filgrastim Drugs 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 230000004547 gene signature Effects 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000035990 intercellular signaling Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 229960002014 ixabepilone Drugs 0.000 description 1
- FABUFPQFXZVHFB-CFWQTKTJSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-CFWQTKTJSA-N 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 208000030173 low grade glioma Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 229960004635 mesna Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 210000003887 myelocyte Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000003643 myeloid progenitor cell Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 238000012148 non-surgical treatment Methods 0.000 description 1
- 230000005937 nuclear translocation Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229960002621 pembrolizumab Drugs 0.000 description 1
- 229960005079 pemetrexed Drugs 0.000 description 1
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000002333 peridermal cell Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- HCWPIIXVSYCSAN-OIOBTWANSA-N radium-223 Chemical compound [223Ra] HCWPIIXVSYCSAN-OIOBTWANSA-N 0.000 description 1
- 229960005562 radium-223 Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012174 single-cell RNA sequencing Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 101150063780 spp1 gene Proteins 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 238000011247 total mesorectal excision Methods 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 230000002476 tumorcidal effect Effects 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000012447 xenograft mouse model Methods 0.000 description 1
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 1
- 229960004276 zoledronic acid Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Developmental Biology & Embryology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
本出願は、2019年2月1日に出願された「組換え遺伝子発現を調節するための微小環境センサー」という名称の米国仮特許出願第62/800,049号の優先権を主張するものであり、この出願は引用によりその全体が本明細書に明示的に援用される。
本願は電子形式の配列表とともに出願されたものである。この配列表は、SCRI207WOSEQLISTのファイル名で2020年1月21日に作成された約105kbのファイルとして提供されたものである。この電子形式の配列表に記載の情報は、引用によりその全体が本明細書に援用される。
本明細書において、「微小環境」は、腫瘍細胞や炎症反応と関連する細胞などの細胞集団の局所的な細胞環境を含んでいてもよい。いくつかの実施形態において、微小環境は、インビボの局所的な細胞環境を含んでいてもよい。微小環境は、周囲血管、免疫細胞、線維芽細胞、骨髄由来炎症性細胞、リンパ球、シグナル伝達分子または細胞外マトリックス(ECM)を含んでいてもよい。微小環境内の状態は、そこに局在する細胞によって特徴付けられてもよく、例えば、ある生物の体循環またはその他のコンパートメントと比較した場合の細胞間シグナル伝達分子の量の増加または減少により特徴付けることができる。微小環境の一例として、腫瘍微小環境(TME)が挙げられる。
本明細書で提供する方法および組成物の実施形態のいくつかは、ポリヌクレオチドを含む。いくつかの実施形態において、このポリヌクレオチドは、治療用ペイロードに作動可能に連結された調節エレメントを含む第1の核酸を含む。いくつかの実施形態において、この調節エレメントは、プロモーターおよび/またはエンハンサーを含んでいてもよい。いくつかの実施形態において、前記調節エレメントは、細胞において治療用ペイロードの特異的な転写を誘導することができるか、そのような転写を誘導するように構成されている。例えば、前記調節エレメントは、特定の刺激に応答して治療用ペイロードの転写を誘導してもよく、この特定の刺激として、例えば、細胞の微小環境に存在するが、その生物の体内のその他の場所には存在しない刺激が挙げられる。いくつかの実施形態において、このような刺激が存在しない場合、転写は起こらないか、または大幅に低減される。例えば、前記刺激が存在しない場合の転写量は、該刺激が存在する場合と比べて、少なくとも50%、60%、70%、80%、90%、95%、98%もしくは100%低下していてもよく、または前記割合のいずれか2つを上下限とする範囲内の割合だけ低下していてもよい。
本明細書で提供する方法および組成物の実施形態のいくつかは、本明細書で開示されたポリヌクレオチドを含むベクターを含む。いくつかの実施形態において、前記ベクターはウイルスベクターを含む。いくつかの実施形態において、前記ベクターは、レンチウイルスベクターまたはレトロウイルスベクターである。いくつかの実施形態において、前記ベクターは、レンチウイルスベクターである。いくつかの実施形態において、前記レンチウイルスベクターは、Vprタンパク質またはその一部とともにパッケージングすることができる。いくつかの実施形態において、前記レンチウイルスベクターは、ウイルスのアクセサリータンパク質とともにパッケージングされる。いくつかの実施形態において、ウイルスのアクセサリータンパク質は、Vif、Vpx、Vpu、NefおよびVprからなる群から選択される。いくつかの実施形態において、ベクターは、キメラ受容体をコードするポリヌクレオチドを含んでいてもよい。
本明細書で提供する方法および組成物の実施形態のいくつかは、細胞を含む。いくつかの実施形態において、細胞は、本明細書で開示されたポリヌクレオチドおよび/またはベクターを含んでいてもよい。例えば、細胞は、治療用ペイロードに作動可能に連結された調節エレメントを含む第1の核酸を含むポリヌクレオチドを含んでいてもよい。そのような実施形態のいくつかにおいて、前記調節エレメントは、細胞において治療用ペイロードの転写を誘導することができるか、そのような転写を誘導するように構成されている。いくつかの実施形態において、細胞は、キメラ受容体をコードするポリヌクレオチドを含んでいてもよい。いくつかの実施形態において、細胞は、キメラ受容体タンパク質を含んでいてもよい。いくつかの実施形態において、細胞は、治療用ペイロードに作動可能に連結された調節エレメント(例えば、細胞において治療用ペイロードの特異的な転写を誘導することができるか、そのような転写を誘導するように構成されている調節エレメント)を含む第1の核酸を含むポリヌクレオチドと、キメラ受容体をコードする別のポリヌクレオチドとを含んでいてもよい。そのような実施形態のいくつかにおいて、前記キメラ受容体は、治療用ペイロードに作動可能に連結された調節エレメントを含む第1の核酸の特異的な転写を誘導する刺激を提供する。
本明細書で提供する方法および組成物の実施形態のいくつかは、キメラ受容体を含む。いくつかの実施形態において、細胞においてキメラ受容体が活性化され、活性化されたキメラ受容体により、該細胞に内在する1つ以上の遺伝子の転写が誘導される。この実施形態の一例を図17Aに示す。いくつかの実施形態において、細胞においてキメラ受容体を活性化することができ、活性化されたキメラ受容体は、本明細書で提供するポリヌクレオチドの特異的な転写を誘導する刺激を提供することができる。この実施形態の一例を図17Bに示す。そのような実施形態のいくつかにおいて、前記ポリヌクレオチドは、治療用ペイロードに作動可能に連結された調節エレメントを含む第1の核酸を含んでいてもよい。
本明細書で提供する方法および組成物の実施形態のいくつかは、治療方法を含む。そのような実施形態のいくつかは、対象において障害を治療、緩和または抑制することを含んでいてもよく、該治療、緩和または抑制は、本明細書で提供する細胞または細胞集団を投与することを含んでいてもよい。いくつかの実施形態において、前記障害は、がん、炎症性障害または炎症性疾患を含んでいてもよい。いくつかの実施形態において、前記対象は哺乳動物である。いくつかの実施形態において、前記対象はヒトである。
本明細書で提供する方法および組成物の実施形態のいくつかは、キットを含む。そのような実施形態のいくつかは、本明細書で提供するポリヌクレオチドを含む。そのような実施形態のいくつかは、本明細書で提供するポリヌクレオチドを含むベクターを含んでいてもよい。いくつかの実施形態において、キットは、治療用ペイロードに作動可能に連結された調節エレメントを含む第1の核酸を含むポリヌクレオチドを含んでいてもよい。そのような実施形態のいくつかにおいて、前記調節エレメントは、細胞において治療用ペイロードの特異的な転写を誘導することができるか、そのような転写を誘導するように構成されている。いくつかの実施形態において、キットは、本明細書で提供するキメラ受容体をコードするポリヌクレオチドを含んでいてもよい。いくつかの実施形態において、キットは、治療用ペイロードに作動可能に連結された調節エレメント(例えば、細胞において治療用ペイロードの特異的な転写を誘導することができるか、そのような転写を誘導するように構成されている調節エレメント)を含む第1の核酸を含む第1のポリヌクレオチドと、本明細書で提供するキメラ受容体をコードする第2のポリヌクレオチドとを含んでいてもよい。そのような実施形態のいくつかにおいて、前記キメラ受容体は、治療用ペイロードに作動可能に連結された調節エレメントを含む第1の核酸の特異的な転写を誘導する刺激を提供することができる。
図1に示す導入遺伝子を構築した。構築した導入遺伝子は、(A)切断型CD19(CD19t)をコードするCD19tコンストラクト;(B)eF1aプロモーターとGFP/ルシフェラーゼレポーター遺伝子とを含むEF1コンストラクト;(C)最小チミジンキナーゼプロモーターとGFP/ルシフェラーゼレポーター遺伝子とを含むminiTKコンストラクト;および(D)連続する3つの低酸素応答エレメント(HRE)と、最小チミジンキナーゼプロモーターと、GFP/ルシフェラーゼレポーター遺伝子とを含むHRE miniTKコンストラクト(HRE_MiniTK eGFP:ffluc -t2a-CD19t)であった。HREは、配列番号44の配列を含んでいた。CD19tは、選択マーカーおよび/または形質導入効率マーカーとして使用した。
単球をGM-CSFで処理して初代ヒトマクロファージを得た。単球から分化したマクロファージを1×103個/ウェルの密度で96穴プレートに播種した。図1に示す導入遺伝子を細胞に形質導入した。7日目に、試験プレートを低酸素チャンバーで24時間インキュベートした(低酸素条件:5% O2、10% CO2、85% N2)。8日目に、形質導入した細胞のルシフェラーゼの発現量を測定した。HRE-MiniTK-ルシフェラーゼコンストラクトの配列の一例を表3に示す。
低酸素応答エレメントとルシフェラーゼレポーター遺伝子とを含む導入遺伝子をヒト293T細胞に形質導入し、低酸素チャンバーでインキュベートした。まず、低酸素チャンバーでインキュベートした形質導入細胞のルシフェラーゼ活性を測定し、次に、低酸素条件を解除した後、通常の条件で形質導入細胞をインキュベートして、0日目、2日目、3日目、4日目および5日目にルシフェラーゼ活性を測定した。通常の条件でインキュベートした形質導入細胞に対する低酸素条件でインキュベートした形質導入細胞の相対ルシフェラーゼ活性を求めた。図8に示すように、低酸素チャンバーから細胞を取り出した後では、相対ルシフェラーゼ活性が低下した。
低酸素条件に晒した後の導入遺伝子の発現を測定した。GM-CSFで分化させた後、形質導入した単球由来のマクロファージを溶解した。細胞抽出物からRNAを単離し、単離したRNAからcDNAを調製した。ローディングコントロールであるβ-アクチンの量を基準として、ルシフェラーゼの量を測定した。ルシフェラーゼの量の測定は、低酸素条件を解除してから0日目、1日目、2日目、3日目および5日目に行った。導入遺伝子として、CD19t(切断型CD19(CD19t)をコードする導入遺伝子);eGFP(eF1aプロモーターとGFP/ルシフェラーゼレポーター遺伝子とを含む導入遺伝子(eF1a eGFP:ffluc-t2a-CD19t));MiniTK(最小チミジンキナーゼプロモーターとGFP/ルシフェラーゼレポーター遺伝子とを含む導入遺伝子(MiniTK eGFP:ffluc-t2a-CD19t));またはHRE(低酸素応答エレメントと、最小チミジンキナーゼプロモーターと、GFP/ルシフェラーゼレポーター遺伝子とを含む導入遺伝子(HRE_MiniTK eGFP:ffluc -t2a-CD19t))をヒト初代マクロファージに形質導入し、このヒト初代マクロファージにおけるルシフェラーゼ転写産物の相対発現量を、低酸素条件の解除後0日目、1日目および2日目に測定し、また、通常の条件を継続した場合(N)でも測定した。
U87細胞皮下移植低酸素モデルを構築した。0日目に、1×106個のU87細胞(ヒト初代膠芽腫細胞株)をマウスに注射し、11日目に、低酸素応答エレメントとルシフェラーゼレポーター遺伝子とを含む試験導入遺伝子(HRE-mTK-ffluc)またはコントロール導入遺伝子(mTK-ffluc)を含む1×106個の遺伝子組換えマクロファージ(GEM)を注射した。図13Aの左図を参照されたい。処置を施した対象において、導入遺伝子のレポーター遺伝子であるルシフェラーゼの発現を1日目、6日目および8日目に測定した(図13A、右図)。
IL-12をコードする遺伝子を含み、eF1aプロモーター(EF1a)、最小チミジンキナーゼプロモーター(MiniTK)、または低酸素応答エレメントと最小チミジンキナーゼプロモーター(HRE MiniTK)で駆動する導入遺伝子を初代ヒトマクロファージに形質導入した。形質導入した細胞を低酸素条件でインキュベートした後、低酸素条件を解除した。0日目と、低酸素条件の解除後1日目、2日目、3日目、4日目および5日目に、IL-12の発現量を測定した。
大腸がん患者から採取した大腸癌試料を薄切し、250μmの厚さの切片を作製した。この切片を、EF1aコンストラクト、MiniTKコンストラクトまたはHRE MiniTK eGFP:ffluc-t2a-CD19tコンストラクトを含む100000個の遺伝子組換えマクロファージ(GEM)とともに低酸素条件で培養した。培養切片において、各コンストラクトを形質導入したGEMからのGFPの発現を測定した。培養物中のGFPの発現量を測定し、GFP+EPCAM+細胞の割合を求めた。図16に示すように、ポジティブコントロールのコンストラクト(EF1a)またはHREコンストラクトを含むGEMとともに培養した培養物は、ネガティブコントロールのコンストラクト(miniTK)を含むGEMとともに培養した培養物よりも高いGFP発現量を示した。
ヒト初代マクロファージに、LILRBドメインと、膜貫通リンカーと、CD3ζ/41BB細胞質内ドメインとを含むキメラ受容体をコードする導入遺伝子を形質導入した。図17Bに示すように、MHCクラスI分子がLILRBドメインに結合すると、CD3ζ/41BBドメインから細胞内シグナル伝達が誘導され、SYKタンパク質のリン酸化が誘導される。このキメラ受容体のポリヌクレオチドの一例を含むベクターのマップを図18Aに示す。リン酸化Sykに応答する調節エレメントを含む導入遺伝子のポリヌクレオチドの一例を含むベクターのマップを図18Bに示す。コントロール細胞は、CD19tマーカーをコードするベクターを形質導入したものである。形質導入した細胞を、MHCクラスI分子を発現する細胞と接触させた。
キメラ受容体の活性をインビトロで調べた。ヒト単球由来マクロファージに、受容体候補としてのMCSF-RxTLR4キメラ受容体1(CR-1)またはMCSF-RxTLR4キメラ受容体2(CR-2)を形質導入した。CR-1を図19Aに示す。CR-2は、CD28膜貫通ドメインの代わりにMCSF受容体の膜貫通ドメインを含むこと以外は、CR-1と実質的に同じものであった。CR-1およびCR-2に含まれるヌクレオチド配列を表4に示す。コントロール細胞は、形質導入を行わなかった細胞である(UT)。細胞をLPS/IFN-γ(10μg/mlおよび100U/ml)で48時間刺激した。上清を回収し、炎症性サイトカインの分析を行った。キメラ受容体を含む細胞は、刺激によりTNF-αおよびIL-12を発現した(図19B)。
膠芽腫腫瘍の切除術を受けた患者から得た腫瘍関連マクロファージと、同じ患者の末梢血から単離した単球を用いて、シングルセルRNAシーケンス解析を行った。腫瘍関連マクロファージでは誘導されていたが、単球では誘導されていなかった遺伝子が400個以上確認され、このことから、これらの遺伝子のプロモーターが腫瘍微小環境(TME)では活性化されるが、末梢循環では活性化されないことが示唆された。
腫瘍微小環境で導入遺伝子を発現させるための別の調節エレメント候補も同定した。神経膠腫の外科的切除術を受けた患者から腫瘍試料を採取し、末梢血も採取した。試料の採取後4時間以内に試料を個々の細胞に分離し、Percoll密度勾配を用いた精製を行い、CD14+細胞を選択した。CD14+細胞をバルクで溶解し、全mRNAの配列を決定した。
Claims (56)
- ポリヌクレオチドであって、
インビボの微小環境内の細胞において治療用ペイロードの転写を誘導することができるか、またはそのような転写を誘導するように構成された調節エレメントを含む第1の核酸;および
前記治療用ペイロードをコードする第2の核酸
を含み、
前記治療用ペイロードが、第1の核酸に作動可能に連結されている、ポリヌクレオチド。 - 前記インビボの微小環境が、腫瘍微小環境および炎症性微小環境から選択される、請求項1に記載のポリヌクレオチド。
- 前記微小環境内の刺激に応答した前記調節エレメントにより特異的な転写が誘導される、請求項1または2に記載のポリヌクレオチド。
- 前記刺激が、体循環と比較した場合の前記微小環境における、血管内皮成長因子(VEGF)、トランスフォーミング成長因子(TGF)、腫瘍壊死因子(TNF)、IL-6、インターフェロン、C3bおよびマクロファージコロニー刺激因子(M-CSF)から選択されるタンパク質の量もしくは該タンパク質をコードする核酸の量の増加;または体循環と比較した場合の前記微小環境における酸素量の減少を含む、請求項3に記載のポリヌクレオチド。
- 前記細胞上のキメラ受容体からの刺激に応答した前記調節エレメントにより特異的な転写が誘導される、請求項1または2に記載のポリヌクレオチド。
- 前記刺激が、リン酸化Sykタンパク質を含む、請求項5に記載のポリヌクレオチド。
- 前記調節エレメントが、腫瘍微小環境内の細胞においてペイロードの特異的な転写の誘導が可能な、もしくはそのような転写を誘導するように構成されたプロモーター、エンハンサーまたはその機能性断片を含む、請求項1~6のいずれか1項に記載のポリヌクレオチド。
- 前記プロモーター、エンハンサーまたはその機能性断片が、APOE、C1QA、SPP1、RGS1、C3、HSPA1B、TREM2、A2M、DNAJB1、HSPB1、NR4A1、CCL4L2、SLC1A3、PLD4、HSPA1A、OLR1、BIN1、CCL4、GPR34、EGR1、HLA-DQA1、FCGR3A、VSIG4、LILRB4、CSF1R、HSPA6、TUBA1B、BHLHE41、GSN、JUN、CX3CR1、HLA-DQB1、HSPE1、FCGR1A、CCL3L1、OLFML3、ADAM28、YWHAH、GADD45B、SLCO2B1、HSP90AA1、HSPA8、RNASET2、HLA-DPA1、CDKN1A、CD83、HAVCR2、DDIT4、C3AR1、HSPD1、LGMN、TMIGD3、CD69、IFI44L、SERPINE1、HLA-DMA、ALOX5AP、EPB41L2、HSP90AB1、HSPH1、RHOB、CH25H、FRMD4A、CXCL16、FCGR1B、HLA-DMB、GPR183、HLA-DPB1、SLC2A5、EGR2、ID2、RGS10、APBB1IP、EVL、CSF2RA、SGK1、FSCN1、BEST1、ADORA3、IFNGR1、MARCKS、MT2A、SRGAP2、ARL5A、ADGRG1、HMOX1、RHBDF2、ATF3、SOCS6、NR4A3、PLK3、APMAP、AKR1B1、UBB、HERPUD1、CTSL、BTG2、IER5、LPAR6、USP53、ST6GAL1、ADAP2、HTRA1、KCNMB1、DNAJA1、LPCAT2、ZFP36L1、CCL3、BAG3、TMEM119、LTC4S、EGR3、FCGBP、ABI3、IFNγ、TNFα、IFNα、IL-6もしくはIL-12に由来するものであるか、またはこれらから選択されたものである、請求項7に記載のポリヌクレオチド。
- 前記調節エレメントが、低酸素応答エレメント(HRE)、SRC結合エレメント、SMAD 2応答エレメント、SMAD 3応答エレメント、ATF結合部位、STAT 2結合部位、CBP結合部位およびSYK結合エレメントから選択されるエレメントを含む、請求項1~8のいずれか1項に記載のポリヌクレオチド。
- 前記調節エレメントがHREを含む、請求項1~9のいずれか1項に記載のポリヌクレオチド。
- 前記治療用ペイロードが、サイトカインをコードする、請求項1~10のいずれか1項に記載のポリヌクレオチド。
- 前記治療用ペイロードが、インターフェロンをコードする、請求項1~10のいずれか1項に記載のポリヌクレオチド。
- 前記インターフェロンが、インターフェロンα、インターフェロンβおよびインターフェロンγから選択される、請求項12に記載のポリヌクレオチド。
- 前記治療用ペイロードが、腫瘍壊死因子(TNF)をコードする、請求項1~10のいずれか1項に記載のポリヌクレオチド。
- 前記TNFが、TNF-α、TNF-β、TNF-γ、CD252、CD154、CD178、CD70、CD153および4-1BBLから選択される、請求項14に記載のポリヌクレオチド。
- 前記治療用ペイロードが、インターロイキンをコードする、請求項1~10のいずれか1項に記載のポリヌクレオチド。
- 前記インターロイキンが、IL-10、IL-12、IL-1、IL-6、IL-7、IL-15、IL-2、IL-18およびIL-21から選択される、請求項16に記載のポリヌクレオチド。
- 前記治療用ペイロードが、ケモカインをコードする、請求項1~10のいずれか1項に記載のポリヌクレオチド。
- 前記ケモカインが、CCL1、CCL2、CCL3、CCR4、CCL5、CCL7、CCL8/MCP-2、CCL11、CCL13/MCP-4、HCC-1/CCL14、CTAC/CCL17、CCL19、CCL22、CCL23、CCL24、CCL26、CCL27、VEGF、PDGF、リンホタクチン(XCL1)、エオタキシン、FGF、EGF、IP-10、TRAIL、GCP-2/CXCL6、NAP-2/CXCL7、CXCL8、CXCL10、ITAC/CXCL11、CXCL12、CXCL13およびCXCL15から選択される、請求項18に記載のポリヌクレオチド。
- 前記調節エレメントが、構成的プロモーターをさらに含む、請求項1~19のいずれか1項に記載のポリヌクレオチド。
- 前記構成的プロモーターが、MiniTKプロモーターおよびEF1αプロモーターから選択される、請求項20に記載のポリヌクレオチド。
- ベクターを含む第3の核酸をさらに含む、請求項1~21のいずれか1項に記載のポリヌクレオチド。
- 前記ベクターが、ウイルスベクターを含む、請求項22に記載のポリヌクレオチド。
- 前記ベクターが、レンチウイルスベクターを含む、請求項23に記載のポリヌクレオチド。
- 請求項1~24のいずれか1項に記載のポリヌクレオチドを含む細胞。
- 細胞外結合ドメイン、膜貫通ドメインおよび細胞内シグナル伝達ドメインを含むキメラ受容体をコードするポリヌクレオチドをさらに含む、請求項25に記載の細胞。
- 前記細胞外結合ドメイン、前記膜貫通ドメインまたは前記細胞内シグナル伝達ドメインが、LILRB受容体、CD115受容体、M-CSF受容体;CXCR4;ニューロピリン(NRP2);上皮成長因子受容体;血管内皮成長因子2型受容体;トランスフォーミング成長因子β 2型受容体;腫瘍壊死因子α受容体;インターロイキン6受容体;インターフェロンγ 2型受容体;顆粒球マクロファージコロニー刺激因子受容体αサブユニット;Toll様受容体4;TGFb、GM-CSF、IL-6、IL-4、IL-1β、IL-13、IL-10、IFN-α、IFN-βまたはIFN-γの受容体を含むサイトカイン受容体;CCR1~10、CXCR1、CXCR2、CXCR3、CXCR4、CXCR5およびCXCR6を含むケモカイン受容体;PDGF、VEGFまたはEGFの受容体を含む成長因子受容体;LPS受容体;LDH受容体;MDH受容体;CpG受容体;ssRNA受容体;ならびに葉酸受容体から選択される受容体に由来するものである、請求項26に記載の細胞。
- 前記細胞外ドメインが、LILRBおよびCD115から選択されるタンパク質の細胞外ドメインに由来するものである、請求項26または27に記載の細胞。
- 前記膜貫通ドメインが、CH3ドメインに連結されたCH2ドメインに連結されたIgG4ヒンジ、CH3ドメインに連結されたIgG4ヒンジ、およびIgG4ヒンジドメインから選択されるタンパク質の膜貫通ドメインに由来するものである、請求項26~28のいずれか1項に記載の細胞。
- 前記細胞内シグナル伝達ドメインが、CD3ζおよび41BBから選択されるタンパク質の細胞内ドメインに由来するものである、請求項26~29のいずれか1項に記載の細胞。
- 免疫細胞である、請求項25~30のいずれか1項に記載の細胞。
- 骨髄系細胞である、請求項31に記載の細胞。
- 好塩基球、好中球、好酸球および単球から選択される、請求項31または32に記載の細胞。
- マクロファージである、請求項31または32に記載の細胞。
- GM-CSFおよび/またはM-CSFに単球を接触させることにより作製されたマクロファージである、請求項31~34のいずれか1項に記載の細胞。
- リンパ系細胞である、請求項31に記載の細胞。
- ナチュラルキラー細胞およびT細胞から選択される、請求項36に記載の細胞。
- 哺乳動物細胞である、請求項25~37のいずれか1項に記載の細胞。
- ヒト細胞である、請求項25~38のいずれか1項に記載の細胞。
- エクスビボの細胞である、請求項25~39のいずれか1項に記載の細胞。
- 対象において障害を治療、抑制または緩和する方法であって、請求項25~41のいずれか1項に記載の細胞を対象に投与することを含む方法。
- 前記障害が、がん、炎症性障害および炎症性疾患から選択される、請求項41に記載の方法。
- 前記障害が、がんである、請求項42に記載の方法。
- 前記がんが、固形腫瘍を含む、請求項43に記載の方法。
- 前記がんが、乳がん、脳腫瘍、肺がん、肝臓がん、胃がん、脾臓がん、大腸がん、腎臓がん、膵臓がん、前立腺がん、子宮がん、皮膚がん、頭部がん、頸部がん、肉腫、神経芽腫、前立腺がんおよび卵巣がんから選択される、請求項42~44のいずれか1項に記載の方法。
- 前記がんが膠芽腫である、請求項42~45のいずれか1項に記載の方法。
- 前記障害が炎症性障害である、請求項42に記載の方法。
- 前記炎症性障害または炎症性疾患が、尋常性ざ瘡、喘息、特定の自己免疫疾患、特定の自己炎症性疾患、セリアック病、慢性前立腺炎、大腸炎、憩室炎、糸球体腎炎、化膿性汗腺炎、特定の過敏症、特定の炎症性腸疾患、間質性膀胱炎、扁平苔癬、マスト細胞活性化症候群、マスト細胞症、耳炎、骨盤炎症性疾患、再灌流障害、リウマチ熱、関節リウマチ、鼻炎、サルコイドーシス、移植拒絶反応、血管炎、急性細菌性感染症、慢性細菌性感染症、移植後関連炎症および移植後関連炎症抑制から選択される、請求項47に記載の方法。
- 前記対象が哺乳動物である、請求項41~48のいずれか1項に記載の方法。
- 前記対象がヒトである、請求項41~49のいずれか1項に記載の方法。
- 医薬品として使用するための、請求項1~24のいずれか1項に記載のポリヌクレオチドまたは請求項25~40のいずれか1項に記載の細胞。
- がんまたは炎症性疾患の治療または緩和のための、請求項1~24のいずれか1項に記載のポリヌクレオチドまたは請求項25~40のいずれか1項に記載の細胞。
- 前記がんが、乳がん、脳腫瘍、肺がん、肝臓がん、胃がん、脾臓がん、大腸がん、腎臓がん、膵臓がん、前立腺がん、子宮がん、皮膚がん、頭部がん、頸部がん、肉腫、神経芽腫、前立腺がん、膠芽腫および卵巣がんから選択される、請求項52に記載のポリヌクレオチドまたは細胞。
- 前記炎症性障害または炎症性疾患が、尋常性ざ瘡、喘息、特定の自己免疫疾患、特定の自己炎症性疾患、セリアック病、慢性前立腺炎、大腸炎、憩室炎、糸球体腎炎、化膿性汗腺炎、特定の過敏症、特定の炎症性腸疾患、間質性膀胱炎、扁平苔癬、マスト細胞活性化症候群、マスト細胞症、耳炎、骨盤炎症性疾患、再灌流障害、リウマチ熱、関節リウマチ、鼻炎、サルコイドーシス、移植拒絶反応、血管炎、急性細菌性感染症、慢性細菌性感染症、移植後関連炎症および移植後関連炎症抑制から選択される、請求項52に記載のポリヌクレオチドまたは細胞。
- 前記対象が哺乳動物である、請求項51~54のいずれか1項に記載のポリヌクレオチドまたは細胞。
- 前記対象がヒトである、請求項51~55のいずれか1項に記載のポリヌクレオチドまたは細胞。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962800049P | 2019-02-01 | 2019-02-01 | |
US62/800,049 | 2019-02-01 | ||
PCT/US2020/015809 WO2020160217A1 (en) | 2019-02-01 | 2020-01-30 | Microenvironment sensors to regulate engineered gene expression |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022519829A true JP2022519829A (ja) | 2022-03-25 |
JPWO2020160217A5 JPWO2020160217A5 (ja) | 2023-02-01 |
Family
ID=71841947
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021544538A Pending JP2022519829A (ja) | 2019-02-01 | 2020-01-30 | 組換え遺伝子発現を調節するための微小環境センサー |
Country Status (8)
Country | Link |
---|---|
US (1) | US20220125951A1 (ja) |
EP (1) | EP3917967A4 (ja) |
JP (1) | JP2022519829A (ja) |
KR (1) | KR20210122814A (ja) |
CN (1) | CN113508178A (ja) |
AU (1) | AU2020214807A1 (ja) |
CA (1) | CA3128350A1 (ja) |
WO (1) | WO2020160217A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20190248A1 (ar) | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
WO2022031936A1 (en) * | 2020-08-06 | 2022-02-10 | The Children's Medical Center Corporation | Compositions for altering a microglial cell, and methods of use therefore |
WO2022251377A1 (en) * | 2021-05-26 | 2022-12-01 | Board Of Regents, The University Of Texas System | Inhibitory chimeric antigen receptor prevents on-target off-tumor effects of adoptive cell therapy |
WO2024068617A1 (en) * | 2022-09-26 | 2024-04-04 | Institut Curie | Myeloid cells expressing il-2 and uses thereof for quick anticancer therapy |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5916763A (en) * | 1995-11-09 | 1999-06-29 | The Regents Of The University Of California | Promoter for VEGF receptor |
WO2007143451A2 (en) * | 2006-05-30 | 2007-12-13 | Terman David S | Targeted delivery of oncolytic viruses, anti-tumor proteins, plasmids, toxins, hemolysins & chemotherapy |
WO2005085455A1 (en) * | 2004-03-09 | 2005-09-15 | Kam Man Hui | Compositions and methods for treating disease |
WO2014138704A1 (en) * | 2013-03-07 | 2014-09-12 | Baylor College Of Medicine | Targeting cd138 in cancer |
-
2020
- 2020-01-30 US US17/424,140 patent/US20220125951A1/en active Pending
- 2020-01-30 KR KR1020217027450A patent/KR20210122814A/ko unknown
- 2020-01-30 EP EP20749739.7A patent/EP3917967A4/en active Pending
- 2020-01-30 WO PCT/US2020/015809 patent/WO2020160217A1/en unknown
- 2020-01-30 CN CN202080017989.0A patent/CN113508178A/zh active Pending
- 2020-01-30 AU AU2020214807A patent/AU2020214807A1/en active Pending
- 2020-01-30 CA CA3128350A patent/CA3128350A1/en active Pending
- 2020-01-30 JP JP2021544538A patent/JP2022519829A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20220125951A1 (en) | 2022-04-28 |
CA3128350A1 (en) | 2020-08-06 |
EP3917967A1 (en) | 2021-12-08 |
CN113508178A (zh) | 2021-10-15 |
WO2020160217A1 (en) | 2020-08-06 |
EP3917967A4 (en) | 2023-02-08 |
AU2020214807A1 (en) | 2021-08-05 |
KR20210122814A (ko) | 2021-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wang et al. | M2b macrophage polarization and its roles in diseases | |
US20240093178A1 (en) | Generating mammalian t cell activation inducible synthetic promoters (syn+pro) to improve t cell therapy | |
JP2022519829A (ja) | 組換え遺伝子発現を調節するための微小環境センサー | |
Guo et al. | Immunobiology of the IL-15/IL-15Rα complex as an antitumor and antiviral agent | |
JP6959909B2 (ja) | 免疫療法のためのマクロファージの遺伝子組換え | |
Brempelis et al. | Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses | |
TW202035685A (zh) | 組合癌症免疫療法 | |
AU2018351689A1 (en) | Targeted gene integration of CRS inhibitor genes for improved immune cells therapy | |
AU2017347637A1 (en) | Targeted gene insertion for improved immune cells therapy | |
AU2017235116A1 (en) | Immunocompetent cell and expression vector expressing regulatory factors of immune function | |
WO2019124468A1 (ja) | ヒトメソセリンを特異的に認識する細胞表面分子、il-7、及びccl19を発現する免疫担当細胞 | |
Sun et al. | STAT3 regulates CD8+ T cell differentiation and functions in cancer and acute infection | |
JP2022512922A (ja) | キメラ抗原受容体記憶様(carml)nk細胞ならびにその産生および使用方法 | |
WO2021259334A1 (zh) | 自我调节型嵌合抗原受体及其在肿瘤免疫中的应用 | |
WO2023123195A1 (zh) | 一种目的基因可调控的工程化免疫细胞及其制备方法和应用 | |
KR20230018378A (ko) | 골수 세포 및 미세아교세포에서 치료 단백질을 특이적으로 발현하는 바이러스 벡터 | |
Buzzai et al. | Diverse Anti-Tumor Immune Potential Driven by Individual IFNα Subtypes | |
US20230279352A1 (en) | Methods for generating primary immune cells | |
Matsushita et al. | Granulocyte‐colony stimulating factor‐induced proliferation of primary adult T‐cell leukaemia cells | |
WO2023088246A1 (zh) | 含gpi锚定区的膜表面蛋白 | |
WO2023234297A1 (ja) | がんを処置するための組成物 | |
WO2023082640A1 (zh) | 增强免疫细胞持久性的方法 | |
CN118147137A (zh) | 生成哺乳动物t细胞活化诱导型合成启动子(syn+pro)以改善t细胞疗法 | |
WO2023010038A1 (en) | Synthetic nucleic acid elements for enhancing car t cell efficacy | |
CN116590343A (zh) | 一种自分泌il-21的nkl-il21细胞系及其构建方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211015 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230123 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230123 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20231228 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240116 |